A detailed history of Charles Schwab Investment Management Inc transactions in Exact Sciences Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,292,090 shares of EXAS stock, worth $75.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,292,090
Previous 1,247,075 3.61%
Holding current value
$75.1 Million
Previous $52.7 Million 66.98%
% of portfolio
0.02%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$42.43 - $70.83 $1.91 Million - $3.19 Million
45,015 Added 3.61%
1,292,090 $88 Million
Q2 2024

Aug 12, 2024

BUY
$41.33 - $74.26 $2.34 Million - $4.21 Million
56,709 Added 4.76%
1,247,075 $52.7 Million
Q1 2024

May 08, 2024

BUY
$56.27 - $73.77 $1.26 Million - $1.66 Million
22,457 Added 1.92%
1,190,366 $82.2 Million
Q4 2023

Feb 06, 2024

BUY
$59.06 - $75.72 $1.82 Million - $2.33 Million
30,831 Added 2.71%
1,167,909 $86.4 Million
Q3 2023

Nov 08, 2023

SELL
$65.94 - $99.04 $38,640 - $58,037
-586 Reduced 0.05%
1,137,078 $77.6 Million
Q2 2023

Aug 09, 2023

BUY
$62.68 - $95.05 $1.1 Million - $1.67 Million
17,555 Added 1.57%
1,137,664 $107 Million
Q1 2023

May 11, 2023

BUY
$47.19 - $70.77 $603,276 - $904,723
12,784 Added 1.15%
1,120,109 $76 Million
Q4 2022

Feb 13, 2023

BUY
$30.35 - $53.15 $1.91 Million - $3.34 Million
62,783 Added 6.01%
1,107,325 $54.8 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $15.2 Million - $23.4 Million
474,199 Added 83.14%
1,044,542 $33.9 Million
Q2 2022

Aug 15, 2022

BUY
$35.61 - $76.23 $868,029 - $1.86 Million
24,376 Added 4.46%
570,343 $22.5 Million
Q1 2022

May 13, 2022

BUY
$57.56 - $82.54 $1.37 Million - $1.96 Million
23,717 Added 4.54%
545,967 $38.2 Million
Q4 2021

Feb 11, 2022

SELL
$72.5 - $100.68 $193,502 - $268,714
-2,669 Reduced 0.51%
522,250 $40.6 Million
Q3 2021

Nov 16, 2021

BUY
$90.24 - $124.05 $721,107 - $991,283
7,991 Added 1.55%
524,919 $50.1 Million
Q2 2021

Aug 16, 2021

BUY
$93.66 - $139.27 $1.56 Million - $2.32 Million
16,649 Added 3.33%
516,928 $64.3 Million
Q1 2021

May 17, 2021

BUY
$116.57 - $155.01 $3.57 Million - $4.75 Million
30,643 Added 6.52%
500,279 $65.9 Million
Q4 2020

Feb 16, 2021

BUY
$99.61 - $142.12 $2.39 Million - $3.41 Million
24,026 Added 5.39%
469,636 $62.2 Million
Q3 2020

Nov 13, 2020

BUY
$72.92 - $102.01 $2.18 Million - $3.06 Million
29,955 Added 7.21%
445,610 $45.4 Million
Q2 2020

Aug 14, 2020

BUY
$55.75 - $92.75 $2.59 Million - $4.3 Million
46,398 Added 12.57%
415,655 $36.1 Million
Q1 2020

May 15, 2020

BUY
$37.9 - $104.44 $258,591 - $712,594
6,823 Added 1.88%
369,257 $21.4 Million
Q4 2019

Feb 07, 2020

BUY
$77.66 - $99.74 $2.42 Million - $3.11 Million
31,144 Added 9.4%
362,434 $33.5 Million
Q3 2019

Nov 08, 2019

SELL
$90.37 - $122.49 $41.5 Million - $56.3 Million
-459,431 Reduced 58.1%
331,290 $29.9 Million
Q2 2019

Aug 09, 2019

BUY
$89.51 - $118.04 $3.25 Million - $4.29 Million
36,316 Added 4.81%
790,721 $93.3 Million
Q1 2019

May 14, 2019

BUY
$61.98 - $96.5 $3.88 Million - $6.04 Million
62,555 Added 9.04%
754,405 $65.3 Million
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $35,641 - $52,571
636 Added 0.09%
691,850 $43.7 Million
Q3 2018

Nov 13, 2018

BUY
$48.29 - $80.6 $2.34 Million - $3.91 Million
48,555 Added 7.56%
691,214 $54.6 Million
Q2 2018

Aug 08, 2018

SELL
$37.84 - $69.96 $7.09 Million - $13.1 Million
-187,433 Reduced 22.58%
642,659 $38.4 Million
Q1 2018

May 07, 2018

BUY
$39.82 - $57.53 $2.57 Million - $3.71 Million
64,570 Added 8.43%
830,092 $33.5 Million
Q4 2017

Jan 17, 2018

BUY
$46.49 - $60.51 $1.94 Million - $2.53 Million
41,784 Added 5.77%
765,522 $40.2 Million
Q3 2017

Nov 13, 2017

BUY
$37.05 - $47.12 $26.8 Million - $34.1 Million
723,738
723,738 $34.1 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.